{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.1","upperLimit":"90.9","value":"86.5"},{"groupId":"OG001","lowerLimit":"76.1","upperLimit":"87.1","value":"82.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"description":"This study utilized a dental effects health scale from 0 (normal) to 4 (life-threatening dental condition). The percentage of participants with a value of 0 or 1 is reported: 0 = \"Normal: Edentulous, with no gingival disease\"; 1 = \"Mild changes/good dental health: mild periodontal inflammation-routine cleaning indicated; \\< 5 restorations indicated; no extractions indicated.\"","dispersionType":"95% Confidence Interval","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started study treatment and had dental status assessment at 2 years after treatment end","reportingStatus":"POSTED","timeFrame":"2 years after end of treatment (approximately 25.5 months)","title":"Percentage of Patients With Normal/Good Dental Health: 2 Years After End of Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}